Group 1 - Costco's shares fell by 3.9% after reporting May comparable sales that were slightly below estimates [1][4] - In May, Costco's comparable sales increased by 4.3%, or 6% when adjusted for fuel prices and foreign exchange, which was lower than the growth rate of 5.8% for the first 39 weeks of the fiscal year [4] - Overall revenue for the four-week period ending June 1 rose by 6.8%, but this was just below the expected adjusted comparable-sales growth of 6.2% [4][5] Group 2 - Wells Fargo noted that despite the slight miss in sales, Costco continues to perform well but has a high valuation, maintaining an equal weight rating with a price target of $1,000 [5] - Costco's current price-to-earnings ratio is 57, indicating high expectations are already factored into the stock price [7] - The market's reaction to a moderation in growth rates suggests that any further disappointing numbers could lead to additional declines in the stock price [6][7]

M&T Bank, Galesi Group forge expanded partnership to fuel Mohawk Harbor's emergence as an entertainment destination SCHENECTADY, N.Y., June 5, 2025 /PRNewswire/ -- M&T Bank (NYSE:MTB) and the Galesi Group have launched a major partnership that will expand their collaborative efforts to accelerate and sustain the revitalization of Schenectady's Mohawk Harbor. Under their agreement, M&T Bank has secured the exclusive naming rights to the new state-of the-art events venue that Galesi Group is building in the h ...

Shares of CoreWeave (CRWV -16.97%) are falling on Thursday, down 16.2% as of 2:13 p.m. ET. The large drop comes as the S&P 500 (^GSPC -0.15%) and the Nasdaq Composite (^IXIC -0.47%) fell by 0.3% and 0.1%, respectively.CoreWeave stock's sharp drop isn't really being driven by specific news from today; rather, it's a retreat from the stock's recent massive run-up. The stock was up nearly 50% this week before today's fall after the company announced several catalysts.CoreWeave inks a key dealCoreWeave, which p ...

Key Takeaways UiPath leads in RPA with strengths in task mining, workflow orchestration, and process optimization. PATH gains momentum from alliances with Microsoft, Amazon, and Salesforce across enterprise ecosystems. UiPath boasts 110-115% net retention and rising earnings estimates amid a growing automation market.UiPath, Inc. (PATH) continues to be a dominant force in the rapidly growing Robotic Process Automation (RPA) market, which QKS Group projects will reach a valuation of $7.9 billion by 2030, w ...

ToplineShares of Tesla dropped by 10% on Thursday as the relationship between Elon Musk and President Donald Trump’s appeared to unravel, with Musk launching attacks at the president on X and Trump suggesting to reporters at the White House criticism of his signature bill from the world’s wealthiest person amounts to “Trump derangement syndrome.”Musk has called to “kill” Trump’s policy bill, criticizing the legislation as “massive, outrageous” ... More and “pork-filled.”AFP via Getty ImagesKey FactsTesla’s ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...

Market Overview - U.S. stocks traded mostly lower, with the Dow Jones falling 0.06% to 42,400.42, NASDAQ down 0.40% to 19,381.93, and S&P 500 decreasing 0.27% to 5,954.96 [1] - Communication services shares increased by 0.4%, while consumer discretionary stocks fell by 1.5% [1] Company Earnings - Ciena Corp reported a quarterly revenue growth of 23.6% year-on-year to $1.13 billion, exceeding analyst expectations of $1.09 billion, but adjusted EPS of 42 cents missed the consensus estimate of 52 cents [2] Stock Movements - Planet Labs PBC shares surged 51% to $6.03 after a first-quarter sales beat and raised FY26 sales guidance [8] - Liminatus Pharma, Inc shares increased 64% to $20.86 after regaining Nasdaq compliance [8] - Owens & Minor, Inc shares rose 17% to $7.78 following the termination of its Rotech Healthcare acquisition [8] - ChargePoint Holdings, Inc shares dropped 23% to $0.6829 after a first-quarter sales miss and lower second-quarter sales guidance [8] - REGENXBIO Inc shares fell 16% to $8.49 after announcing new data from a clinical trial [8] - PVH Corp shares decreased 17% to $66.92 after cutting FY25 guidance and issuing lower second-quarter adjusted EPS guidance [8] Commodity Prices - Oil prices increased by 0.8% to $63.34, while gold prices decreased by 0.8% to $3,373.80 [5] - Silver prices rose 3.1% to $35.735, and copper prices increased by 0.7% to $4.9215 [5] International Markets - European shares were mostly higher, with the eurozone's STOXX 600 rising 0.16% and Spain's IBEX 35 Index increasing by 0.73% [6] - Asian markets closed higher, with Japan's Nikkei down 0.51%, Hong Kong's Hang Seng Index up 1.07%, China's Shanghai Composite gaining 0.23%, and India's BSE Sensex increasing by 0.55% [7]

Key Takeaways NRG is trading above its 50-day and 200-day SMAs, signaling a sustained bullish price trend. Strong earnings, data center demand, and acquisitions are fueling NRG's growth momentum. NRG's ROE exceeds peers, and it targets 7-9% annual dividend growth over the long term.NRG Energy Inc. (NRG) is trading above its 50-day and 200-day simple moving averages ("SMA"), signaling a bullish trend. NRG’s shares have gained steadily over the past 12 months after the earnings beat in three out of the trai ...

MAIA Biotechnology, Inc. MAIA on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc’s REGN immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy.As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who rec ...

Core Insights - Planet Labs has achieved a significant milestone by reporting break-even profits and a record sales figure of $66.3 million in its fiscal Q1 2026 earnings report, surpassing analyst expectations [2][4] - The company experienced a 10% year-over-year increase in sales, with 97% of its revenue being recurring, indicating strong customer retention and business stability [4] - For the first time, Planet Labs reported positive free cash flow of $8 million, although it still recorded a GAAP loss of $0.04 per share [5] Financial Performance - Analysts had anticipated a loss of $0.03 per share on sales of $62.3 million, but the actual sales were $66.3 million, leading to a stock price increase of 52.1% [2] - Gross profit margins improved from 52% in the previous year to 55% in the latest quarter, reflecting enhanced operational efficiency [4] - The company projects fiscal Q2 sales to be approximately $66 million, which is expected to be flat sequentially but up about 8% year-over-year [6] Future Outlook - For the full fiscal year, Planet Labs anticipates sales growth between 9% and 15%, targeting total sales of $265 million to $280 million [7] - Despite expectations of negative earnings and free cash flow for the year, the company is moving closer to achieving sustainable free cash flow, which may enhance its investment appeal [7]